Trial Profile
Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Oct 2022 Status changed from active, no longer recruiting to completed.
- 28 Jun 2022 Planned End Date changed from 1 Jun 2021 to 1 Sep 2022.
- 26 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.